Epicatechin and catechin modulate endothelial activation induced by platelets of patients with peripheral artery disease

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Carnevale, R ^a   Loffredo, L ^a   Nocella, C ^a   Bartimoccia, S ^a   Bucci, T ^a   De Falco, E ^a   Peruzzi, M ^a   Chimenti, I ^a   Biondi Zoccai, G ^a   Pignatelli, P ^a   Violi, F ^a   Frati, G ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CELL ADHESION; CELLS; CHEMICAL ACTIVATION; DISEASES; ENDOTHELIAL CELLS; FLAVONOIDS; NITRIC OXIDE; ORGANIC COMPOUNDS; PHENOLS;

ACTIVATED PLATELETS; CELL ADHESION MOLECULES; ENDOTHELIAL FUNCTION; EPICATECHIN; FLOW MEDIATED DILATION; HEALTHY SUBJECTS; PERIPHERAL ARTERY DISEASE; PLATELET ACTIVATION;

PLATELETS;

8 ISOPROSTAGLANDIN F2 ALPHA; CATECHIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPICATECHIN; NITRIC OXIDE; VASCULAR CELL ADHESION MOLECULE 1; CELL ADHESION MOLECULE; NITROGEN OXIDE; NOS3 PROTEIN, HUMAN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BIOAVAILABILITY; BLOOD FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME PHOSPHORYLATION; FEMALE; FLOW MEDIATED DILATATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN SECRETION; SUPERNATANT; THROMBOCYTE ACTIVATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VASODILATATION; AGED; CROSS-SECTIONAL STUDY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PERIPHERAL ARTERIAL DISEASE; PHOSPHORYLATION; THROMBOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CATECHIN; CELL ADHESION MOLECULES; CROSS-SECTIONAL STUDIES; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; NITROGEN OXIDES; PERIPHERAL ARTERIAL DISEASE; PHOSPHORYLATION; PLATELET ACTIVATION;

EID: 84925884549     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/691015     Document Type: Article

References (32)

1. W. Insull Jr., "The pathology of atherosclerosis: plaque development and plaque responses to medical treatment,"The American Journal of Medicine, vol. 122, no. 1, supplement, pp.S3-S14, 2009.
2. J. I. Borissoff,H.M.H. Spronk, andH.T.Cate, "The hemostatic system as a modulator of atherosclerosis," The New England Journal of Medicine, vol. 364, no. 18, pp. 1746-1760, 2011.
3. S. M. Schoenwaelder, Y. Yuan, E. C. Josefsson et al., "Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function," Blood, vol. 114, no. 3, pp. 663-666, 2009.
4. J. E. Italiano Jr., J. L. Richardson, S. Patel-Hett et al., "Angiogenesis is regulated by a novelmechanism: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released," Blood, vol. 111, no. 3, pp. 1227-1233, 2008.
5. J. D. Pearson, "Normal endothelial cell function," Lupus, vol. 9, no. 3, pp. 183-188, 2000.
6. M. T. Gentile, C. Vecchione, G. Marino et al., "Resistin impairs insulin-evoked vasodilation," Diabetes, vol. 57, no. 3, pp. 577-583, 2008.
7. G. R. Wang, Y. Zhu, P. V. Halushka, T. M. Lincoln, and M. E. Mendelsohn, "Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 9, pp. 4888-4893, 1998.
8. Y. Ohara, T. E. Peterson, and D. G. Harrison, "Hypercholesterolemia increases endothelial superoxide anion production," Journal of Clinical Investigation, vol. 91, no. 6, pp. 2546-2551, 1993.
9. D. D. Wagner and P. S. Frenette, "The vessel wall and its interactions," Blood, vol. 111, no. 11, pp. 5271-5281, 2008.
10. G. Brevetti, A. Silvestro, V. Schiano, and M. Chiariello, "Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial desease : additive value of flow-mediate dilatation to ankle-brachial pressure index," Circulation, vol. 108, no. 17, pp. 2093-2098, 2003.
11. C. Heiss, T. Lauer, A. Dejam et al., "Plasma nitroso compounds are decreased in patients with endothelial dysfunction," Journal of the American College of Cardiology, vol. 47, no. 3, pp. 573-579, 2006.
12. L. Loffredo, R. Carnevale, R. Cangemi et al., "NOX2 upregulation is associated with artery dysfunction in patients with peripheral artery disease," International Journal of Cardiology, vol. 165, no. 1, pp. 184-192, 2013.
13. J. K. Bendall, R. Rinze, D. Adlam, A. L. Tatham, J. de Bono, and K. M. Channon, "Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II: Studies in endothelial-targeted Nox2 transgenic mice," Circulation Research, vol. 100, no. 7, pp. 1016-1025, 2007.
14. O. Jung, J. G. Schreiber, H. Geiger, T. Pedrazzini, R. Busse, and R. P. Brandes, "gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension," Circulation, vol. 109, no. 14, pp. 1795-1801, 2004.
15. M. de Lorgeril, P. Salen, J. L. Martin, I. Monjaud, J. Delaye, and N. Mamelle, "Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications aftermyocardial infarction: final report of the Lyon Diet Heart Study," Circulation, vol. 99, no. 6, pp. 779-785, 1999.
16. T. L. Zern and M. L. Fernandez, "Cardioprotective effects of dietary polyphenols," Journal of Nutrition, vol. 135, no. 10, pp. 2291-2294, 2005.
17. O. Vitseva, S. Varghese, S. Chakrabarti, J. D. Folts, and J. E. Freedman, "Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates," Journal of Cardiovascular Pharmacology, vol. 46, no. 4, pp. 445-451, 2005.
18. P. Pignatelli, A. Ghiselli, B. Buchetti et al., "Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine," Atherosclerosis, vol. 188, no. 1, pp. 77-83, 2006.
19. R. Carnevale, L. Loffredo, P. Pignatelli et al., "Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers," Journal of Thrombosis and Haemostasis, vol. 10, no. 1, pp. 125-132, 2012.
20. C.Menna, E. de Falco, L. Pacini, G. Scafetta, P. Ruggieri, and R. Puca, "Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture," Cancer Investigation, vol. 32, no. 1, pp. 13-21, 2014.
21. S. W. Hoffman, R. L. Roof, and D. G. Stein, "A reliable and sensitive enzyme immunoassay method for measuring 8- isoprostaglandin F(2α): a marker for lipid peroxidation after experimental brain injury," Journal of Neuroscience Methods, vol. 68, no. 2, pp. 133-136, 1996.
22. P. Pignatelli, R. Carnevale, R. Cangemi et al., "Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 2, pp. 360-367, 2010.
23. M. C. Corretti, T. J. Anderson, E. J. Benjamin et al., "Guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force," Journal of the American College of Cardiology, vol. 39,no. 2, pp. 257-265, 2002.
24. L. Loffredo, A. Marcoccia, P. Pignatelli et al., "Oxidativestress- mediated arterial dysfunction in patients with peripheral arterial disease," European Heart Journal, vol. 28, no. 5, pp. 608- 612, 2007.
25. A. T. Hirsch, Z. J. Haskal, N. R. Hertzer et al., "ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee toDevelop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation," Circulation, vol. 113, no. 11, pp. e463-e654, 2005.
26. R. Ross, "Atherosclerosis-an inflammatory disease," The New England Journal of Medicine, vol. 340, no. 2, pp. 115-126, 1999.
27. T. Dickfeld, E. Lengyel, A. E. May et al., "Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogenactivated protein kinase mediated pathway: implications for atherogenesis," Cardiovascular Research, vol. 49, no. 1, pp. 189-199, 2001.
28. A. G. Kjærgaard, A. Dige, J. Krog, E. Tønnesen, and L. Wogensen, "Soluble adhesion molecules correlate with surface expression in an in vitro model of endothelial activation," Basic and Clinical Pharmacology and Toxicology, vol. 113, no. 49, pp. 273-279, 2013.
29. R. Joannides, W. E. Haefeli, L. Linder et al., "Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo," Circulation, vol. 91,no. 5, pp. 1314-1319, 1995.
30. R. Bruckdorfer, "The basics about nitric oxide," Molecular Aspects of Medicine, vol. 26, no. 1-2, pp. 3-31, 2005.
31. D. M. Dudzinski and T.Michel, "Life history of eNOS: partners and pathways," Cardiovascular Research, vol. 75, no. 2, pp. 247-260, 2007.
32. L. Loffredo, L. Perri, E. Catasca et al., "Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease," Journal of the American Heart Association, vol. 3, Article ID e001072, 2014.